TY - JOUR
T1 - Symptomatic Treatment of Extrapyramidal Hyperkinetic Movement Disorders
AU - de Boer, Gregory
AU - de Bie, Robertus Maria Alfonsius
AU - Sylvain Swinnen, Bart Erik Kris
N1 - Publisher Copyright:
© 2024 Bentham Science Publishers.
PY - 2024/5/20
Y1 - 2024/5/20
N2 - Extrapyramidal hyperkinetic movement disorders comprise a broad range of phenotypic phenomena, including chorea, dystonia, and tics. Treatment is generally challenging and individualized, given the overlapping phenomenology, limited evidence regarding efficacy, and concerns regarding the tolerability and safety of most treatments. Over the past decade, the treatment has become even more intricate due to advancements in the field of deep brain stimulation as well as optimized dopamine-depleting agents. Here, we review the current evidence for treatment modalities of extrapyramidal hyperkinetic movement disorders and provide a comprehensive and practical overview to aid the choice of therapy. Mechanism of action and practical intricacies of each treatment modality are discussed, focusing on dosing and adverse effect management. Finally, future therapeutic developments are also discussed.
AB - Extrapyramidal hyperkinetic movement disorders comprise a broad range of phenotypic phenomena, including chorea, dystonia, and tics. Treatment is generally challenging and individualized, given the overlapping phenomenology, limited evidence regarding efficacy, and concerns regarding the tolerability and safety of most treatments. Over the past decade, the treatment has become even more intricate due to advancements in the field of deep brain stimulation as well as optimized dopamine-depleting agents. Here, we review the current evidence for treatment modalities of extrapyramidal hyperkinetic movement disorders and provide a comprehensive and practical overview to aid the choice of therapy. Mechanism of action and practical intricacies of each treatment modality are discussed, focusing on dosing and adverse effect management. Finally, future therapeutic developments are also discussed.
KW - botulinum toxin
KW - deep brain stimulation
KW - Extrapyramidal
KW - hyperkinetic
KW - medication
KW - movement disorders
KW - neuropharmacology
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=85203825487&partnerID=8YFLogxK
U2 - 10.2174/1570159X22666240517161444
DO - 10.2174/1570159X22666240517161444
M3 - Review article
C2 - 38847380
AN - SCOPUS:85203825487
SN - 1570-159X
VL - 22
SP - 2284
EP - 2297
JO - Current Neuropharmacology
JF - Current Neuropharmacology
IS - 14
ER -